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ABSTRACT 
Objectives: Curcumin, a known hMAO-A (human Monoamine oxidase-A) inhibitor from Curcuma longa has never been recognized for this property 
due to its poor permeability and extensive metabolism. Thus, the main objective of this study is to incorporate structural features of Curcumin in the 
pyrazoline scaffold as an attempt to get potent, selective hMAO-isoform inhibitors with improved permeability. 
Methods: A series of twelve novel 4, 4'-(4, 5-dihydro-1H-pyrazole-3,5-diyl)bis(2-methoxyphenol) derivatives (1-12) were designed based on the 
structure of Curcumin. All the designed compounds were evaluated for their hMAO inhibitory activity by in-silico docking studies (Autodock4.20). 
The both isomers (R-and S-isomer) are considered for simulation approach to understand the effect of chirality and other structural features that 
determine the potency and selectivity. In order to judge the pharmacokinetic behavior, all the derivatives were evaluated for their in-silico ADME 
properties by using Qik Prop v 3.0. 
Results: The results of the present study showed that all the designed compounds were found to be potent and selective hMAO-isoform inhibitors, 
and exhibited lead like properties from the calculated ADME parameters. Curcumin was taken as a standard for comparison to judge any 
improvement in permeability. 
Conclusion: The design strategy adopted has predicted improved potency, selective towards hMAO-isoform and permeability characteristics in 
comparison with Curcumin. 




Monoamine oxidases are FAD (Flavin adenine dinucleotide) 
containing enzymes located on the mitochondrial outer membrane 
exists in two different isoforms, MAO-A and MAO-B. They metabolize 
dietary amines, neurotransmitters, are identified by the difference in 
their specificity towards their substrate and their selective inhibitors 
[1, 2]. Serotonin, adrenaline, and noradrenaline are preferably 
metabolized by MAO-A [3], while β-phenylethylamine and 
benzylamine by MAO-B [4]. Tyramine, dopamine, and some other 
important amines are common substrates for both the MAO-isoforms 
[5]. MAO-inhibitors introduced earlier were abandoned from clinical 
practice mainly due to their adverse effects; these adverse effects were 
mainly attributed to non-selective inhibition of isoforms. In the past 
decade, the interest in MAO inhibitors got renewed due to the fact that 
isoform-selective inhibitors, that are reversible, are showing potential 
therapeutic utility in the treatment of depression (MAO-A selective) 
and neurodegenerative disorders (MAO-B selective) [6–8]. 
Earlier few researcher synthesized pyrazoline derivatives and stated 
that the calculated (Ki value) obtained from the molecular docking 
studies (by AutoDock) concerning the hMAO inhibitory activities of 
the compounds were found to be in a good agreement with the 
experimental Ki value [9,10]. Thus, the present study in-silico 
docking has been performed to understand the interactions of 
Curcumin-based pyrazoline derivatives (1-12), which are crucial for 
their hMAO-isoform inhibitory activity. In-silico ADME parameters 
have also been performed by QikProp v 3.0.  
Rationale of designing potent and selective hMAO-isoform 
inhibitors 
Curcumin, a natural compound with proven MAO inhibitory and 
antidepressant activity [11–16]. As curcumin was having poor 
bioavailability [17], it is never recognized as a good antidepressant due 
to its poor permeability and bioavailability. The half-life (t1/2) of 
Curcumin in phosphate buffered saline (PBS) at pH 7.2 was less than 10 
min due to extensive metabolism [18]. In humans, Moclobemide (MOC) 
is rapidly and almost completely absorbed and totally metabolized by 
the liver [19], about 44 percent of the drug is lost due to the first pass 
effect through the liver [20]. The elimination half-life is around 2 h [21]. 
Selegiline (SEL) has a low oral bioavailability, which increases to 
moderate when ingested together with a high-fat meal, the molecule 
being fat soluble [22]. Selegiline oral bioavailability is drastically 
increased in females taking oral contraceptives (10-to 20-fold) [23]. This 
could lead to lose of MAO-B selectivity in favor of an MAO-A selectivity, 
which in turn would make patients susceptible to the usual risks of non-
selective hMAO-inhibitors such as tyramine-induced hypertensive [23].  
The novel pyrazoline derivatives (1-12) have been designed by 
utilizing the structural features in Curcumin. We design chalcone 
that resembles aryl-α,β-unsaturated carbonyl portion of Curcumin 
but by reversing the position of the double bond and the carbonyl 
group, then chalcone was cyclized to provide a series of novel 
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Table 1: Structure of designed novel pyrazolines (1-12) 
 
Compound R Compound R 












































MATERIALS AND METHODS 
Molecular docking studies were carried on RHEL-5.0 Operating 
system installed on Dell Precision workstation with Intel core 2 
quad processor and 8 GB RAM by using AutoDock4.2 (The Sripps 
Research Institute) [24]. 
Molecular docking simulation procedures 
In order to understand the interaction at the molecular level, 
compounds 1-12 were docked with X-ray crystal structure of hMAO-
A (PDB: 2BXR) and hMAO-B (PDB: 2BYB) using AutoDock4.2 
docking protocol reported earlier [25-30].  
Ligand preparation 
Ligand structures were drawn using build panel and prepared using 
Ligprep module implemented Maestro-8.4 (Schrodinger LLC). 
Energy minimization is carried out using OPLS 2005 force field. 
Structures were saved in PDB format for AutoDock compatibility. 
MGL Tools-1.5.6 (The Sripps Research Institute) was used to convert 
ligand. pdb files to the ligand. PDB qt files. 
Protein preparation 
X-ray crystal structure of hMAO-A (PDB ID: 2BXR) and hMAO-B (PDB 
ID: 2BYB) were downloaded from protein data bank (www. rcsb. org). 
Protein preparation wizard Maestro-8.4 (Schrodinger LLC) was used 
to prepare protein. Water molecules were removed from the protein, 
FAD was reconstructed, side chains were optimized for hydrogen 
bonding and finally energy minimized using OPLS 2001 force field. The 
protein was then saved in the PDB format. Using MGL Tools-1.5.6 
nonpolar hydrogens were merged, assigned AD4.2 type, Gasteiger 
charges and finally saved in protein. PDB qt format. 
Docking protocol 
For docking, grid parameter file (. gpf) and docking parameter files (. 
dpf) were written using MGL Tools-1.5.6. Receptor grids were 
generated using 60×60×60 Grid points in xyz with a grid spacing of 
0.375Å. Grid box was centered on N5 atom of FAD. Map types were 
generated using Autogrid 4.2. Docking was carried out with 
following parameters with a number of runs: 50, population size: 
150, the number of evaluations: 2,500,000 and number of 
generations: 27,000, using Autodock 4.2.  
Autodock run 
Both protein and ligand were selected as a. PDB qt file from 
“docking”. Autodock was run for each ligand. Docking output was 
obtained as a. dlg format. Analysis of docking results was done using 
MGL Tools-1.5.6. A Top scoring molecule in the largest cluster was 
analyzed for its interaction with the protein. 
ADME parameters prediction 
ADME parameters were calculated using QikProp v 3.0 tools of 
Schrodinger software [31]. Qik Prop provides ranges for comparing 
an exact molecule’s properties with those of 95% of known drugs. 
QikProp also flags 30 types of reactive functional groups that may 
cause false positives in high throughput screening assays. It also 
evaluates the suitability of derivatives based on Lipinski’s rule of 
five [32-35], which is essential to ensure drug-like pharmacokinetic 
profile while using rational drug design. All the analogs were 
neutralized before being used by Qik Prop v3.0. 
RESULTS AND DISCUSSION 
Molecular docking simulation  
Molecular docking simulation was carried out to understand the 
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potency and selectivity of designed novel pyrazoline derivatives (1-
12). The 5C carbon of pyrazoline is chiral in nature and two isomers 
are possible. In the presented work, we considered both the R-and S-
isomer to check the effect of chirality on potency and selectivity 
towards hMAO-isoforms. From the simulation results it seems the 
substituent’s at 1Nposition of pyrazoline has some effect in determining 
the potency of the isomers (R-isomer and S-isomer). Except compound 1 
was found to be hMAO-B selective, when there is no substitution at 1N 
position of pyrazoline, while other compounds (2-12) having 
substituent’s at 1N position of pyrazoline increase in bulkiness and shifts 
selectivity towards MAO-A isoform with increase in potency too 
according to the Inhibitory constant (Ki) values obtained by docking 
analysis. Ki values are represented in table 2. According to the calculated 
Ki values, compound 8 exhibited the highest hMAO-A inhibitory activity, 
with higher SI than the standard drug Moclobemide SI. R-isomers of 
compounds (2, 6-8 and 10-12) were found to perform better than S-
isomer, while in case of compounds (3, 5 and 9) S-isomer were found to 
perform better than R-isomer. Compound 4 R-and S-isomers were found 
to be equipotent towards hMAO-isoforms. For comparison ki value 
obtained by Autodock studies, the averages of R-and S-isomers were 
calculated for each isoform, and their isomer potency and selectivity 
index were calculated for better understanding. SI was calculated as Ki 
(MAO-A)/Ki(MAO-B). Selectivity towards MAO-A increases as the 
corresponding SI decreases while selectivity towards MAO-B isoform 
increases as the corresponding SI increases. Curcumin, SEL and MOC 
selectivity index was considered instead of selectivity MAO-Arac/MAO-
Brac. (table 2). In order to understand the factors that contribute towards 
the selectivity and potency of the docked complexes of potent 
compounds (R-and S-isomers) were studied for their orientation and 
interactions in active site cavity of hMAO-isoforms were discussed below 
which sheds a light on the key structural features responsible for their 
potency and selectivity.  
Orientation of compounds (1-12) in active site of hMAO-A  
R-isomers compound 10 ring A at 3rd position of pyrazoline towards 
pocket 2 (lined by Ile180, Ile335, Leu337, Met350 and Phe352). Ring B 
at the 5th position of pyrazoline orient towards pocket 3 (lined by Gly74, 
Arg206, Ile207, Phe208, Glu216 and Trp441) and 1N-substitution of 
pyrazoline towards pocket 1 (aromatic cage lined by FAD, Tyr407, and 
Tyr444). All other compounds ring B towards the aromatic cage, ring A 
towards pocket 3, 1N-substituent’s towards pocket 2.  
Orientation of compounds (1-12) in active site of hMAO-A  
S-isomers Compound 1 orient in such a way that ring A towards 
pocket 3, ring B towards pocket 2, this will keep the aromatic cage 
empty. Compound (2-6 and 9-12) having 1N substituents fills the 
aromatic cage while rings A and ring B orient same as compound 1. 
Compound 7 and 8 having similar orientation ring A towards pocket 
3 (same as compound 1-6 and 9-12) but ring B towards pocket 1 and 
1N-substituents towards pocket 2, and these may be the reason that 
1N-substituted pyrazolines exhibit selectivity towards hMAO-A 
isoform. Compound 8 having the bulkier substitution at 1N position 
than compound 7 these may be the reason why compound 8 having 
better Ki value than compound 7. 
Interaction of compound (3) with hMAO-A  
S-isomer Phenyl ring (Ring A) at 3rd position of pyrazoline towards 
pocket 3, ring A establishes π-π interaction with Trp441 and with FAD, 
moreover ring A hydroxy oxygen forms a hydrogen bond with the 
oxygen of Pro72. Phenyl ring (Ring B) at the 5th position of pyrazoline 
occupy pocket 2, and establishes π-π interaction with Tyr69. This places 
the substitution at 1N position to orient towards pocket 1, establishes π-
π interaction with Tyr69, this may be the reason that S-isomer shows 
better (Ki value), potency and selectivity than R-isomer fig. 2. 
Interaction of compound (3) with hMAO-A  
R-isomer Phenyl ring (Ring A) at 3rd position of pyrazoline occupy 
pocket 3, and ring A establishes π-π interaction with Trp441. Phenyl 
ring (Ring B) at the 5th position of pyrazoline occupy pocket 1. The 
substitution at 1N position of pyrazoline orient towards pocket 2 fig. 3.  
Interaction of compound (8) with hMAO-A  
R-isomer Phenyl ring (Ring A) at 3rd position of pyrazoline occupy pocket 
3, and establishes π-π interaction with Trp441and Phe352. Phenyl ring 
(Ring B) at the 5th position of pyrazoline towards pocket 1 and 
establishes π-π interaction with Phe352, moreover ring B-hydroxy 
oxygen forms a hydrogen bond with the oxygen of Tyr407. The 
substitution at 1N position of pyrazoline orient towards pocket 2 fig. 4. 
Orientation of compounds (1-12) in active site of hMAO-B 
R-isomers compound 11 ring A towards aromatic cage (formed by 
FAD, Tyr435, and Tyr398). Ring B and 1N-substituents of 
pyrazolines towards hydrophobic pocket (characterized by LEU171, 
TYR326, PHE168, ILE198, and ILE199). All other compounds ring B 
and 1N-substitution towards the aromatic cage, while ring A 
towards the hydrophobic cage.  
Orientation of compounds (1-12) in active site of hMAO-B 
S-isomers compound 8 ring A and ring B towards aromatic cage 
(formed by FAD, Tyr435, and Tyr398), and 1N-substitutituents 
towards the hydrophobic pocket, all other compounds ring B and 
1N-substitution towards aromatic cage and ring A towards the 
hydrophobic cage. 
Interaction of compound (1) with hMAO-B 
R-isomer Phenyl ring (Ring B) at the 5rd position of pyrazoline orient 
towards the aromatic cage, the hydroxy group of ring B established H-
bonding interaction with 5N of FAD, this interaction is mainly stabilized 
by the strongπ-π interaction between Bring of the compound 1and the 
FAD. Phenyl ring (Ring A) at the 3th position of pyrazoline keeps in the 
hydrophobic pocket and anchoring from their face of FAD with a 
distance of 3.564 Å, moreover establishes π-π interaction with Tyr435 
fig. 5. 
 

























R S R S 
1 2.20 5.36 0.41 3.78 0.296 0.493 0.600406 0.789 4.79 MAO-B 
2 1.87 4.83 0.38 3.35 247.51 3.32 74.5512 250.83 0.01 MAO-A 
3 61.66 0.035 1761.71 30.84 - 258.92 - - - MAO-A 
4 0.151 0.151 1 0.15 35350 - - - - MAO-A 
5 0.376 0.196 1.91 0.28 203310 - - - - MAO-A 
6 0.090 0.192 0.46 0.14 266.12 143000 0.001 143266.1 9x10-7 MAO-A 
7 0.750 2.85 0.263 1.8 9220 3.09 2983.81 9223.09 0.000195 MAO-A 
8 0.281 0.483 0.58 0.38 - - - - - MAO-A 
9 0.441 0.238 1.85 0.33 9910 44.09 224.76 9954.09 0.00003 MAO-A 
10 0.423 1.20 0.35 0.81 6.89 0.925 7.44 7.815 0.10 MAO-A 
11 1.71 6.72 0.25 4.21 216.73 10.65 20.35 227.38 0.01 MAO-A 
12 9.13 20.27 0.45 14.7 72910 186.57 390.79 73096.57 0.000201 MAO-A 
Curcumin 0.602 - - 16.40 - - 0.036 MAO-A 
MOC 7.91 - - 12.13 - - 0.652 MAO-A 
SEL 78.26 - - 93.62 - - 0.835 MAO-B 
Badavath et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 12, 277-282 
280 
 
Fig. 2: Interaction of S-enantiomer of Compound (3) with hMAO-
A (PDB: 2BXR) active site, H-bonds are shown as green dots and 
π-π interaction as yellow cylinders 
 
 
Fig. 3: Interaction of R-enantiomer of Compound (3) with 
hMAO-A (PDB: 2BXR) active site, H-bonds are shown as green 
dots and π-π interaction as yellow cylinders 
 
Fig. 4: Interaction of R-enantiomer of Compound (8) with 
hMAO-A (PDB: 2BXR) active site, H-bonds are shown as green 
dots and π-π interaction as yellow cylinders 
 
 
Fig. 5: Interaction of R-enantiomer of Compound (1) with 
hMAO-B (PDB: 2BYB) active site, H-bonds are shown as green 
dots and π-π interaction as yellow cylinders 
 





Log Po/w Log S Log BB PMDCK Human oral absorption (%) Lipinski’s violations 
1 (R) C17H18N2O4 314.34 2.467 -4.166 -0.931 263.777 90.564 0 
1 (S) 2.477 -4.238 -0.958 255.304 90.387 0 
2 (R) C19H20N2O5 356.37 2.669 -4.694 -1.065 204.091 89.899 0 
2 (S) 2.669 -4.694 -1.065 203.993 89.894 0 
3 (R) C24H22N2O5 418.44 3.832 -5.476 -1.044 247.981 100 0 
3 (S) 3.83 -5.471 -1.044 247.944 100 0 
4 (R) C23H22N2O6S 454.50 3.374 -5.279 -1.309 169.404 92.62 0 
4 (S) 2.789 -4.182 -1.218 142.414 87.882 0 
5 (R) C24H24N2O6S 468.52 3.666 -5.814 -1.354 169.137 94.319 0 
5 (S) 3.059 -4.52 -1.222 145.353 89.606 0 
6 (R) C24H22N2O6 434.44 4.048 -6.078 -1.092 274.421 100 0 
6 (S) 4.049 -6.08 -1.091 274.542 100 0 
7 (R) C20H22N2O6 386.40 3.27 -5.38 -1.179 205.149 93.455 0 
7 (S) 3.27 -5.382 -1.18 204.793 93.445 0 
8 (R) C24H23N3O4S 449.52 4.733 -6.648 -0.629 1172.325 100 0 
8 (S) 4.678 -6.428 -0.592 1201.794 100 0 
9 (R) C23H22N2O4 390.43 4.879 -6.379 -0.617 653.791 100 0 
9 (S) 4.88 -6.379 -0.617 653.51 100 0 
10 (R) C18H19N3O4S 373.43 2.699 -4.91 -0.847 575.814 91.096 0 
10 (S) 2.699 -4.91 -0.848 575.465 91.093 0 
11 (R) C18H19N3O5 357.36 1.415 -3.063 -1.526 67.614 68.59 0 
11 (S) 1.416 -3.065 -1.527 67.571 68.591 0 
12 (R) C18H20N4O4 356.38 2.042 -4.069 -1.673 61.088 77.555 0 
12 (S) 2.042 -4.068 -1.672 61.086 77.555 0 
Curcumin C21H20O6 368.38 2.96 -4.349 -1.897 128.192 88.259 0 
MOC C13H17ClN2O2 268.739 1.829 -2.233 0.378 978.137 89.028 0 
SEL C13H17N 187.281 3.093 -2.09 0.646 1396.996 100 0 
 
ADME parameterss 
All the designed pyrazoline derivatives (1-12) R-and S-isomer were 
subjected for their predictive ADME parameters with their R and S-
isomers, for physical descriptors and pharmaceutically significant 
properties of pyrazoline derivatives using QikProp v3.0 tool of 
Schrodinger software, among which major descriptors reported here 
are required for predicting the drug-like properties of molecules.  
These properties are:  
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1. Molecular weight (Mol. Wt.) (150-650) 
2. Octanol/water partition coefficient (Log Po/w) (-2-6.5) 
3. Aqueous solubility (QPlogS) ( −6.5-0.5) 
4. Apparent Madin–Darby canine kidney (MDCK) cell permeability 
(QPPMDCK) (<25 poor,>500 great) 
5. Brain/blood partition coefficient (QPlogBB) ( −3.0-1.2) 
6. Percent human oral absorption ( ≥80% is high, ≤25% is poor). 
All the novel designed pyrazoline derivatives (1-12) (R-and S-
isomers) showed significant drug-like characteristics based on 
Lipinski’s rule of 5. table 3. The designed pyrazoline derivatives 
follow the three properties of Lipinski rule of five (Mol. Wt.)<650, 
(logPo/w) between −2 to  6.5 and (QPlogS)>−7. (QPlogBB) 
parameter indicated the ability of the drug to pass through the 
blood-brain barrier which is mandatory for selective hMAO-B 
inhibition. The QPPMDCK predicted apparent MDCK cell 
permeability in nm/s. MDCK cells are considered to be a good 
mimic for the blood-brain barrier and higher the value of 
QPPMDCK, higher the cell permeability. All designed compounds 
showed ADME parameters in an acceptable range. 
CONCLUSION  
All the designed pyrazoline derivatives (1-12) were found to be 
potent and selective hMAO-isoform inhibitory activity than 
Curcumin. The results obtained by docking studies could be utilized 
for the development of novel pyrazoline derivatives with potent and 
selective hMAO-isoform inhibitory activity. The result of ADME 
parameters showed that all the designed pyrazolines exhibit lead like 
properties. The design strategy adopted has significantly improved the 
permeability characteristics in comparison with Curcumin. 
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